ArticleCureus2025
A Protocol for Venous Thromboembolism Prophylaxis in Elective Spine Surgery: A Retrospective Evaluation of a Single-Center Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVenous thromboembolic (VTE) events include deep vein thrombosis (DVT) and pulmonary embolism (PE). In spine surgery, the risk of VTE events should be weighed against the risk of developing epidural hematoma (EDH). This has made the subject of VTE prophylaxis in spine surgery an ongoing matter of debate in the scientific community.
objectiveTo present our experience with venous thromboembolism prophylaxis in patients undergoing elective spine surgery and discuss it in the light of the literature.
methodsThis was a retrospective review done on all patients who underwent elective spine surgery at our institution from 2019 to 2024 and were prescribed a specified VTE prophylaxis protocol (inpatient enoxaparin and a seven-day course of rivaroxaban following discharge). Patients who underwent spine surgery for non-elective indications, were known to have a malignancy, had a history of VTE, were already on anticoagulant therapy, and/or were non-ambulatory, were excluded.
resultsA total of 528 patients were included; 284 (53.78%) patients were males, and 354 (67.04%) surgeries were thoraco-lumbar. Of the 174 (32.95%) surgeries performed on the cervical spine, 105 were anterior discectomies and 69 were laminectomies. The mean age (±SD) was 55.06 years (±14.9). The majority of the included patients were overweight/obese; 447 patients (84.65%). Of all the patients, 452 (85.6%) started to ambulate on Day 1, and the mean (±SD) length of hospital stay was comparable for patients undergoing cervical and thoracolumbar spine surgeries, 4.6 (±1.3) and 4.8 (±1.6), respectively. None of the patients experienced VTE events, while three (0.56%) developed EDH.
conclusionThe protocol presented in this report is safe and effective in preventing VTE in ambulatory patients undergoing elective spine surgery. Rivaroxaban is a possible option for VTE prophylaxis in patients undergoing elective spine surgery, including procedures involving the cervical spine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.